Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Cash from Operations (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed Cash from Operations for 13 consecutive years, with 47408.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations fell 21.32% year-over-year to 47408.0, compared with a TTM value of 179636.0 through Nov 2025, up 15.07%, and an annual FY2025 reading of 171305.0, up 29.87% over the prior year.
  • Cash from Operations was 47408.0 for Q4 2025 at CNBX Pharmaceuticals, down from 28545.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 20517.0 in Q3 2023 and bottomed at 702340.0 in Q1 2021.
  • Average Cash from Operations over 5 years is 207748.55, with a median of 61932.5 recorded in 2023.
  • The sharpest move saw Cash from Operations skyrocketed 113.72% in 2023, then crashed 23219.56% in 2025.
  • Year by year, Cash from Operations stood at 599545.0 in 2021, then soared by 84.0% to 95915.0 in 2022, then increased by 25.09% to 71846.0 in 2023, then soared by 45.61% to 39077.0 in 2024, then dropped by 21.32% to 47408.0 in 2025.
  • Business Quant data shows Cash from Operations for CNBX at 47408.0 in Q4 2025, 28545.0 in Q3 2025, and 52019.0 in Q2 2025.